Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (33)

2024

  1. Workflow to facilitate the detection of new psychoactive substances and drugs of abuse in influent urban wastewater

    Journal of Hazardous Materials, Vol. 469

2023

  1. Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs

    Environment International, Vol. 178

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  3. Three years of wastewater surveillance for new psychoactive substances from 16 countries

    Water Research X, Vol. 19

  4. Wastewater-Based Epidemiology for the Assessment of Human Exposure to Environmental Pollutants

    Elsevier, pp. 1-261

  5. Wastewater-based epidemiology as a surveillance tool to assess human consumption of psychotropic substances: Alcohol, nicotine and caffeine as case studies

    TrAC - Trends in Analytical Chemistry, Vol. 167

2021

  1. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  2. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

2020

  1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  2. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  3. Editorial: Artificial Intelligence in Chemistry

    Frontiers in Chemistry

  4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  6. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

  7. Spatio-temporal assessment of illicit drug use at large scale: evidence from 7 years of international wastewater monitoring

    Addiction, Vol. 115, Núm. 1, pp. 109-120

2019

  1. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873

  2. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 5, pp. 1418-1429

  3. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018

    Allergy: European Journal of Allergy and Clinical Immunology